卡介苗无应答性膀胱癌患者派姆单抗耐药相关分子特征的空间比较

medRxiv - Urology Pub Date : 2023-11-30 DOI:10.1101/2023.11.28.23299093

Khyati Meghani, Noah Frydenlund, Yanni Yu, Bonnie Choy, Joshua J. Meeks

{"title":"卡介苗无应答性膀胱癌患者派姆单抗耐药相关分子特征的空间比较","authors":"Khyati Meghani, Noah Frydenlund, Yanni Yu, Bonnie Choy, Joshua J. Meeks","doi":"10.1101/2023.11.28.23299093","DOIUrl":null,"url":null,"abstract":"<strong>Background</strong> Intravenous immune checkpoint inhibition achieves a 40% three-month response in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). Yet only half of early responders will continue to be disease free by 12 months, and resistance mechanisms are poorly defined.","PeriodicalId":501140,"journal":{"name":"medRxiv - Urology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Spatial Comparison of Molecular Features Associated with Resistance to Pembrolizumab in BCG Unresponsive Bladder Cancer\",\"authors\":\"Khyati Meghani, Noah Frydenlund, Yanni Yu, Bonnie Choy, Joshua J. Meeks\",\"doi\":\"10.1101/2023.11.28.23299093\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<strong>Background</strong> Intravenous immune checkpoint inhibition achieves a 40% three-month response in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). Yet only half of early responders will continue to be disease free by 12 months, and resistance mechanisms are poorly defined.\",\"PeriodicalId\":501140,\"journal\":{\"name\":\"medRxiv - Urology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"medRxiv - Urology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1101/2023.11.28.23299093\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2023.11.28.23299093","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

背景:静脉注射免疫检查点抑制对bcg无反应的非肌肉浸润性膀胱癌(NMIBC)合并原位癌(CIS)的三个月应答率为40%。然而，只有一半的早期应答者能在12个月内持续无病，而且耐药机制也不明确。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

A Spatial Comparison of Molecular Features Associated with Resistance to Pembrolizumab in BCG Unresponsive Bladder Cancer

Background Intravenous immune checkpoint inhibition achieves a 40% three-month response in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). Yet only half of early responders will continue to be disease free by 12 months, and resistance mechanisms are poorly defined.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

medRxiv - Urology

自引率

0.00%

发文量